De rol van de rRNA-modificaties en lncRNA-afgeleide micropeptiden bij herbedrading van melanoom translatie en therapieresistentie KU Leuven
In metastatic melanoma, despite the recent breakthroughs in targeted therapy and Immune Checkpoint Blockade (ICB), the 5-year survival rate remains around 54%. This is at least in part due to the high plasticity of melanoma cells and their ability to quickly switch between different drug-tolerant states upon therapy exposure, allowing them to escape this threat. Phenotype switching into an undifferentiated drug-tolerant state can be induced ...